{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:50:36Z","timestamp":1762271436278},"publisher-location":"Berlin, Heidelberg","reference-count":63,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642004766"},{"type":"electronic","value":"9783642004773"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-3-642-00477-3_16","type":"book-chapter","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T15:54:00Z","timestamp":1266422040000},"page":"469-489","source":"Crossref","is-referenced-by-count":12,"title":["Medical Devices for the Treatment of Eye Diseases"],"prefix":"10.1007","author":[{"given":"Tsutomu","family":"Yasukawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,19]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111\u2013118","journal-title":"Retina"},{"key":"16_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1350-9462(01)00018-0","volume":"21","author":"J Ambati","year":"2002","unstructured":"Ambati J, Adamis AP (2002) Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res 21:145\u2013151","journal-title":"Prog Retin Eye Res"},{"key":"16_CR3","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/S0161-6420(00)00562-5","volume":"107","author":"American Academy of Ophthalmology","year":"2000","unstructured":"American Academy of Ophthalmology (2000) Photodynamic therapy with verteporfin for age-related macular degeneration. Ophthalmology 107:2314\u20132317","journal-title":"Ophthalmology"},{"key":"16_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000027378","volume":"212","author":"D Armstrong","year":"1998","unstructured":"Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, Koch F (1998) Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 212:410\u2013414","journal-title":"Ophthalmologica"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2005.09.002","volume":"113","author":"AJ Augustin","year":"2006","unstructured":"Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:14\u201322","journal-title":"Ophthalmology"},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1126\/science.277.5322.112","volume":"277","author":"B Autran","year":"1997","unstructured":"Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debr\u00e9 P, Leibowitch J (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112\u2013116","journal-title":"Science"},{"key":"16_CR7","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007a) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179\u20132182","journal-title":"Ophthalmology"},{"key":"16_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007b) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855\u2013859","journal-title":"Ophthalmology"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/archopht.120.10.1307","volume":"120","author":"MS Blumenkranz","year":"2002","unstructured":"Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mon\u00d5s JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2002) Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: 3-year results of an open-label extension of 2 randomized clinical trials\u2013TAP Report no. 5. Arch Ophthalmol 120:1307\u20131314","journal-title":"Arch Ophthalmol"},{"key":"16_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/17469899.2.1.33","volume":"2","author":"DG Callanan","year":"2007","unstructured":"Callanan DG (2007) Novel intravitreal fluocinolone acetonide implant in the treatment of chronic noninfectious posterior uveitis. Expert Rev Ophthalmol 2:33\u201344","journal-title":"Expert Rev Ophthalmol"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0161-6420(89)32900-9","volume":"96","author":"WH Cantrill","year":"1989","unstructured":"Cantrill WH, Henry K, Melroe NH, Knobloch WH, Ramsay RC, Balfour HH (1989) Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 96:367\u2013374","journal-title":"Ophthalmology"},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/bjo.77.5.265","volume":"77","author":"U Chakravarthy","year":"1993","unstructured":"Chakravarthy U, Houston RF, Archer DB (1993) Treatment of age-related subfoveal neovascular membranes by teletherapy. Br J Ophthalmol 77:265\u2013273","journal-title":"Br J Ophthalmol"},{"key":"16_CR14","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S0161-6420(91)32135-3","volume":"98","author":"I Cocherau-Massin","year":"1991","unstructured":"Cochereau-Massin I, Lehoang P, Lautier-Frau M, Zazoun L, Marcel P, Robinet M, Matheron S, Katlama C, Gharakhanian S, Rozenbaum W, et al. (1991) Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 98:1348\u20131355","journal-title":"Ophthalmology"},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s004170050239","volume":"237","author":"C Eckardt","year":"1999","unstructured":"Eckardt C, Eckardt U, Conrad HG (1999) Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 237:313\u2013325","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"16_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1136\/bjo.85.4.461","volume":"85","author":"IA El-Ghrably","year":"2001","unstructured":"El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ (2001) Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol 85:461\u2013470","journal-title":"Br J Ophthalmol"},{"key":"16_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0169-409X(01)00193-4","volume":"52","author":"DH Geroski","year":"2001","unstructured":"Geroski DH, Edelhauser HF (2001) Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 52:37\u201348","journal-title":"Adv Drug Deliv Rev"},{"key":"16_CR18","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ophtha.2006.02.065","volume":"113","author":"MC Gillies","year":"2006","unstructured":"Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema. 2-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533\u20131538","journal-title":"Ophthalmology"},{"key":"16_CR19","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/S0161-6420(95)30857-3","volume":"102","author":"G Gonzalez-Avila","year":"1995","unstructured":"Gonzalez-Avila G, Lozano D, Manjarrez ME, Ruiz VM, Ter\u00c3n L, Vadillo-Ortega F, Selman M (1995) Influence on collagen metabolism of vitreous from eyes with proliferative vitreoretinopathy. Ophthalmology 102:1400\u20131405","journal-title":"Ophthalmology"},{"key":"16_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0161-6420(90)32552-6","volume":"97","author":"JB Gross","year":"1990","unstructured":"Gross JB, Bozzete SA, Mathews WC, Spector SA, Abramson IS, McCutchan JA, Mendez T, Munguia D, Freeman WR (1990) Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 97:681\u2013686","journal-title":"Ophthalmology"},{"key":"16_CR21","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1001\/archopht.1989.01070020849025","volume":"107","author":"MH Heinemann","year":"1989","unstructured":"Heinemann MH (1989) Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 107:1767\u20131772","journal-title":"Arch Ophthalmol"},{"key":"16_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0161-6420(87)33454-2","volume":"94","author":"DE Henderly","year":"1987","unstructured":"Henderly DE, Freeman WR, Causey DM, Rao NA (1987) Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 94:425\u2013434","journal-title":"Ophthalmology"},{"key":"16_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/sj.eye.6700190","volume":"16","author":"DR Hinton","year":"2002","unstructured":"Hinton DR, He S, Jin ML, Barron E, Ryan SJ (2002) Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 16:422\u2013428","journal-title":"Eye"},{"key":"16_CR24","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/archopht.1986.01050240068042","volume":"104","author":"GN Holland","year":"1986","unstructured":"Holland GN, Sakamoto MJ, Hardy D, Sidikaro Y, Kreiger AE, Frenkel LM (1986) Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxyl-1-(hydroxy-methyl)ethoxymethyl] guanine. Arch Ophthalmol 104:1794\u20131800","journal-title":"Arch Ophthalmol"},{"key":"16_CR25","first-page":"345","volume":"20","author":"A Hueber","year":"1996","unstructured":"Hueber A, Wiedemann P, Esser P, Heimann K (1996\u20131997) Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR). Int Ophthalmol 20:345\u2013350","journal-title":"Int Ophthalmol"},{"key":"16_CR26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0002-9394(14)72131-2","volume":"122","author":"M Ip","year":"1996","unstructured":"Ip M, Gorin MB (1996) Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. Am J Ophthalmol 122:594\u2013595","journal-title":"Am J Ophthalmol"},{"key":"16_CR27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/archopht.122.8.1131","volume":"122","author":"MS Ip","year":"2004","unstructured":"Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, Gangnon RE, Puliafito CA (2004) Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 122:1131\u20131136","journal-title":"Arch Ophthalmol"},{"key":"16_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0161-6420(87)33535-3","volume":"94","author":"DA Jabs","year":"1987","unstructured":"Jabs DA, Newman C, De Bustros S, Polk BF (1987) Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 94:824\u2013830","journal-title":"Ophthalmology"},{"key":"16_CR29","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0161-6420(00)00466-8","volume":"107","author":"GJ Jaffe","year":"2000","unstructured":"Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P (2000) Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 107:2024\u20132033","journal-title":"Ophthalmology"},{"key":"16_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0161-6420(89)32818-1","volume":"96","author":"JA Jerdan","year":"1989","unstructured":"Jerdan JA, Pepose JS, Michels RG, Hayashi H, de Bustros S, Sebag M, Glaser BM (1989) Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 96:801\u2013810","journal-title":"Ophthalmology"},{"key":"16_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bjo.80.2.101","volume":"80","author":"H Kaplan","year":"1996","unstructured":"Kaplan H (1996) Submacular surgery for choroidal neovascularization. Br J Ophthalmol 80:101","journal-title":"Br J Ophthalmol"},{"key":"16_CR32","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1167\/iovs.06-0670","volume":"48","author":"SH Kim","year":"2007","unstructured":"Kim SH, Galban CJ, Lutz RJ, Dedrick RL, Csaky KG, Lizak MJ, Wang NS, Tansey G, Robinson MR (2007) Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci 48:808\u2013814","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"16_CR33","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0161-6420(92)31871-8","volume":"99","author":"R Klein","year":"1992","unstructured":"Klein R, Klein BEK, Linton KLP (1992) Prevalence of age-related maculopathy: the beaver dam eye study. Ophthalmology 99:933\u2013943","journal-title":"Ophthalmology"},{"key":"16_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0168-3659(00)00267-4","volume":"68","author":"N Kunou","year":"2000","unstructured":"Kunou N, Ogura Y, Yasukawa T, Kimura H, Miyamoto H, Honda Y, Ikada Y (2000) Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release 68:263\u2013271","journal-title":"J Controlled Release"},{"key":"16_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0002-9394(02)01536-2","volume":"134","author":"EC Heij La","year":"2002","unstructured":"La Heij EC, van de Waarenburg MP, Blaauwgeers HG, Kessels AG, Liem AT, Theunissen C, Steinbusch H, Hendrikse F (2002) Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am J Ophthalmol 134:367\u2013375","journal-title":"Am J Ophthalmol"},{"key":"16_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0169-409X(95)00012-V","volume":"16","author":"LC Lang","year":"1995","unstructured":"Lang LC (1995) Ocular drug delivery: conventional ocular formulations. Adv Drug Deliv Rev 16:39\u201343","journal-title":"Adv Drug Deliv Rev"},{"key":"16_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9394(75)90862-4","volume":"80","author":"R Machemer","year":"1975","unstructured":"Machemer R, Laqua H (1975) Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol 80:1\u201323","journal-title":"Am J Ophthalmol"},{"key":"16_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1001\/archopht.1986.01050160059012","volume":"104","author":"Macular Photocoagulation Study Group","year":"1986","unstructured":"Macular Photocoagulation Study Group (1986) Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 104:503\u2013512","journal-title":"Arch Ophthalmol"},{"key":"16_CR39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/archopht.1990.01070080067037","volume":"108","author":"Macular Photocoagulation Study Group","year":"1990","unstructured":"Macular Photocoagulation Study Group (1990) Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 108:825\u2013831","journal-title":"Arch Ophthalmol"},{"key":"16_CR40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/archopht.1994.01090160056023","volume":"112","author":"Macular Photocoagulation Study Group","year":"1994","unstructured":"Macular Photocoagulation Study Group (1994a) Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112:480\u2013488","journal-title":"Arch Ophthalmol"},{"key":"16_CR41","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/archopht.1994.01090160076025","volume":"112","author":"Macular Photocoagulation Study Group","year":"1994","unstructured":"Macular Photocoagulation Study Group (1994b) Laser photocoagulation for juxtafoveal choroidal neovascularization: 5-year results from randomized clinical trials. Arch Ophthalmol 112:500\u2013509","journal-title":"Arch Ophthalmol"},{"key":"16_CR42","first-page":"S233","volume":"42","author":"MG Maguire","year":"2001","unstructured":"Maguire MG, Fine SL, Maguire AM, D'Amato RJ, Singerman LJ (2001) Results of the age-related macular degeneration and thalidomide study (AMDATS). Invest Ophthalmol Vis Sci 42:S233","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"16_CR43","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J (2008) Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N Engl J Med 358:2240\u20132248","journal-title":"N Engl J Med"},{"key":"16_CR44","volume-title":"Pharmacology of the eye","author":"DM Maurice","year":"1984","unstructured":"Maurice DM, Mishima S (1984) Ocular pharmacokinetics. In: Sears ML (ed) Pharmacology of the eye. Springer, New York"},{"key":"16_CR45","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1167\/iovs.02-0260","volume":"44","author":"I Milenkovic","year":"2003","unstructured":"Milenkovic I, Weick M, Wiedemann P, Reichenbach A, Bringmann A (2003) P2Y receptor-mediated stimulation of Muller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation. Invest Ophthalmol Vis Sci 44:1211\u20131220","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"16_CR46","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/bjo.83.6.652","volume":"83","author":"SM Mitchell","year":"1999","unstructured":"Mitchell SM, Membrey WL, Youle MS, Obi A, Worrell S, Gazzard BG (1999) Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol 83:652\u2013655","journal-title":"Br J Ophthalmol"},{"key":"16_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0161-6420(95)31010-X","volume":"102","author":"MG Morley","year":"1995","unstructured":"Morley MG, Duker JS, Ashton P, Robinson MR (1995) Replacing ganciclovir implants. Ophthalmology 102:388\u2013392","journal-title":"Ophthalmology"},{"key":"16_CR48","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1167\/iovs.02-0956","volume":"44","author":"K Okabe","year":"2003","unstructured":"Okabe K, Kimura H, Okabe J, Kato A, Kunou N, Ogura Y (2003) Intraocular tissue distribution of betamethasone after intrascleral administration using a nonbiodegradable sustained drug delivery device. Invest Ophthalmol Vis Sci 44:2702\u20132707","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"16_CR49","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/S0002-9394(02)01641-0","volume":"134","author":"G Pertile","year":"2002","unstructured":"Pertile G, Glaes C (2002) Macular translocation with 360-degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol 134:560\u2013565","journal-title":"Am J Ophthalmol"},{"key":"16_CR50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archopht.1997.01100160035005","volume":"115","author":"Pharmacological Therapy for Macular Degeneration Study Group","year":"1997","unstructured":"Pharmacological Therapy for Macular Degeneration Study Group (1997) Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 115:865\u2013872","journal-title":"Arch Ophthalmol"},{"key":"16_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0161-6420(83)34588-7","volume":"90","author":"Retinal Society Terminology Committee","year":"1983","unstructured":"Retinal Society Terminology Committee (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90:121\u2013125","journal-title":"Ophthalmology"},{"key":"16_CR52","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"16_CR53","volume-title":"Retina","author":"SJ Ryan","year":"1994","unstructured":"Ryan SJ, Stout JT, Dugel PU (1994) Subretinal neovascularization. In: Ryan SJ (ed) Retina. Mosby, St. Louis"},{"key":"16_CR54","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/archopht.1992.01080140044023","volume":"110","author":"GE Sanborn","year":"1992","unstructured":"Sanborn GE, Anald R, Torti RE, Nightingale SD, Cal SX, Yates B, Ashton P, Smith T (1992) Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol 110:188\u2013195","journal-title":"Arch Ophthalmol"},{"key":"16_CR55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF02172967","volume":"226","author":"OF Scheiffarth","year":"1988","unstructured":"Scheiffarth OF, Kampik A, Gunther H, von der Mark K (1988) Proteins of the extracellular matrix in vitreoretinal membranes. Graefes Arch Clin Exp Ophthalmol 226:357\u2013361","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"16_CR56","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/archopht.1992.01080140111037","volume":"110","author":"TJ Smith","year":"1992","unstructured":"Smith TJ, Pearson PA, Blandford DL, Brown JD, Goins KA, Hollins JL, Schmeisser ET, Glavinos P, Baldwin LB, Ashton P (1992) Intravitreal sustained-release ganciclovir. Arch Ophthalmol 110:255\u2013258","journal-title":"Arch Ophthalmol"},{"key":"16_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0161-6420(99)90060-X","volume":"106","author":"DTH Tan","year":"1999","unstructured":"Tan DTH, Chee SP, Lim L, Lim ASM (1999) Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 106:223\u2013231","journal-title":"Ophthalmology"},{"key":"16_CR58","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0161-6420(88)33147-7","volume":"95","author":"FM Ussery","year":"1988","unstructured":"Ussery FM, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ (1988) Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 95:640\u2013648","journal-title":"Ophthalmology"},{"key":"16_CR59","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0161-6420(98)97031-2","volume":"105","author":"TR Vrabec","year":"1998","unstructured":"Vrabec TR, Baldassano VF, Whitcup SM (1998) Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 105:1259\u20131264","journal-title":"Ophthalmology"},{"key":"16_CR60","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s004170050031","volume":"238","author":"T Yasukawa","year":"2000","unstructured":"Yasukawa T, Kimura H, Kunou N, Miyamoto H, Honda Y, Ogura Y, Ikada Y (2000) Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch Clin Exp Ophthalmol 238:186\u2013190","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"16_CR61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1517\/17425247.3.2.261","volume":"3","author":"T Yasukawa","year":"2006","unstructured":"Yasukawa T, Ogura Y, Kimura H, Sakurai E, Tabata Y (2006) Drug delivery from ocular implants. Expert Opin Drug Deliv 3:261\u2013273","journal-title":"Expert Opin Drug Deliv"},{"key":"16_CR62","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.preteyeres.2004.02.003","volume":"23","author":"T Yasukawa","year":"2004","unstructured":"Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y (2004) Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 23:253\u2013281","journal-title":"Prog Retin Eye Res"},{"key":"16_CR63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1586\/17469899.2.2.197","volume":"2","author":"T Yasukawa","year":"2007","unstructured":"Yasukawa T, Tabata Y, Kimura H, Kunou N, Ogura Y (2007) Development of drug-delivery systems to the posterior segments of the eye. Expert Rev Ophthalmol 2:197\u2013211","journal-title":"Expert Rev Ophthalmol"}],"container-title":["Handbook of Experimental Pharmacology","Drug Delivery"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-00477-3_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T08:00:35Z","timestamp":1558857635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-00477-3_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,19]]},"ISBN":["9783642004766","9783642004773"],"references-count":63,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-00477-3_16","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2009,11,19]]}}}